Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients
Authors:
- S. Matthijs BoekholdtSBS. Matthijs Boekholdt
- Benoit J. ArsenaultBABenoit J. Arsenault
- G. Kees HovinghGHG. Kees Hovingh
- Samia MoraSMSamia Mora
- Terje R. PedersenTPTerje R. Pedersen
- John C. LaRosaJLJohn C. LaRosa
- K.M.A. WelchKWK.M.A. Welch
- Pierre AmarencoPAPierre Amarenco
- David A. DeMiccoDDDavid A. DeMicco
- Andrew M. TonkinATAndrew M. Tonkin
- David R. SullivanDSDavid R. Sullivan
- Adrienne KirbyAKAdrienne Kirby
- 1 October 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 128 (14) , 1504-1512
Abstract
Background—: It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether a rise in HDL-C or apoA-I after initiation of statin therapy is associated with a reduced cardiovascular risk. Methods and Results—: We performed a meta-analysis of 8 statin trials in which lipids and apolipoproteins were determined in all study participants at baseline and at 1-year follow-up. Individual patient data were obtained for 38 153 trial participants allocated to statin therapy, of whom 5387 suffered a major cardiovascular event. HDL-C levels were associated with a reduced risk of major cardiovascular events (adjusted hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.81–0.86 per 1 standard deviation increment), as were apoA-I levels (HR, 0.79; 95% CI, 0.72–0.82). This association was also observed among patients achieving on-statin low-density lipoprotein cholesterol levels <50 mg/dL. An increase of HDL-C was not associated with reduced cardiovascular risk (HR, 0.98; 95% CI, 0.94–1.01 per 1 standard deviation increment), whereas a rise in apoA-I was (HR, 0.93; 95% CI, 0.90–0.97). Conclusions—: Among patients treated with statin therapy, HDL-C and apoA-I levels were strongly associated with a reduced cardiovascular risk, even among those achieving very low low-density lipoprotein cholesterol. An apoA-I increase was associated with a reduced risk of major cardiovascular events, whereas for HDL-C this was not the case. These findings suggest that therapies that increase apoA-I concentration require further exploration with regard to cardiovascular risk reduction.Keywords
This publication has 31 references indexed in Scilit:
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Reconstituted HDL Elicits Marked Changes in Plasma Lipids Following Single-Dose Injection in C57Bl/6 MiceJournal of Cardiovascular Pharmacology and Therapeutics, 2011
- Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery DiseaseJACC, 2011
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Prevalence of coronary heart disease in the framingham offspring study: Role of lipoprotein cholesterolsThe American Journal of Cardiology, 1980